0MGB Stock Overview
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Genmab A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.2,084.42 |
52 Week High | kr.2,946.00 |
52 Week Low | kr.1,824.50 |
Beta | 0.76 |
1 Month Change | 5.64% |
3 Month Change | -2.69% |
1 Year Change | -18.90% |
3 Year Change | -0.12% |
5 Year Change | 77.32% |
Change since IPO | 507.28% |
Recent News & Updates
Recent updates
Shareholder Returns
0MGB | GB Biotechs | GB Market | |
---|---|---|---|
7D | 2.0% | 1.7% | 2.2% |
1Y | -18.9% | -27.5% | 3.7% |
Return vs Industry: 0MGB exceeded the UK Biotechs industry which returned -27.5% over the past year.
Return vs Market: 0MGB underperformed the UK Market which returned 3.7% over the past year.
Price Volatility
0MGB volatility | |
---|---|
0MGB Average Weekly Movement | 4.6% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0MGB has not had significant price volatility in the past 3 months.
Volatility Over Time: 0MGB's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 2,204 | Jan G.J. van Winkel | https://www.genmab.com |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
Genmab A/S Fundamentals Summary
0MGB fundamental statistics | |
---|---|
Market cap | kr.135.86b |
Earnings (TTM) | kr.4.35b |
Revenue (TTM) | kr.16.47b |
31.2x
P/E Ratio8.2x
P/S RatioIs 0MGB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0MGB income statement (TTM) | |
---|---|
Revenue | kr.16.47b |
Cost of Revenue | kr.226.00m |
Gross Profit | kr.16.25b |
Other Expenses | kr.11.90b |
Earnings | kr.4.35b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | 66.76 |
Gross Margin | 98.63% |
Net Profit Margin | 26.42% |
Debt/Equity Ratio | 0% |
How did 0MGB perform over the long term?
See historical performance and comparison